• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention relates to a novel methylated cyclodextrin, as well as to a novel process useful in its preparation. The invention also relates to the use of this methylated cyclodextrin for the solubilization of lipophilic compounds, or carriers of at least one lipophilic group. The invention also relates to a composition comprising this methylated cyclodextrin, in particular a pharmaceutical composition.
    公开号:FR3042501A1
    申请号:FR1559832
    申请日:2015-10-16
    公开日:2017-04-21
    发明作者:Xavier Parissaux；Jean-Baptiste Palmieri；Mathias Ibert；Clothilde Buffe
    申请人:Roquette Freres SA；
    IPC主号:
    专利说明:

    Methylated cyclodextrins and methods for their preparation
    The present invention relates to a novel methylated cyclodextrin, as well as to a novel process useful in its preparation. The invention also relates to the use of this methylated cyclodextrin for the solubilization of lipophilic compounds or carriers of at least one lipophilic group. The invention also relates to a composition comprising this methylated cyclodextrin, in particular a pharmaceutical composition.
    Context of the Invention
    Cyclodextrins are cyclic oligosaccharides derived from the enzymatic degradation of starch. The three most common natural cyclodextrins consist of 6, 7 or 8 α-D-glucopyranose units in chair configuration interconnected by α-1,4 linkages. They are more commonly called α, β, or cyclodextrin, respectively. Their three-dimensional structure appears in the form of a truncated cone outside of which are the hydroxyl groups representing the highly hydrophilic part of the cyclodextrins. The interior of the cone or the cavity of the cyclodextrins is constituted by the hydrogen atoms carried by the C3 and C5 carbons as well as by the oxygen atoms participating in the glycoside bond, thus conferring on them an apolar character.
    Cyclodextrins having a hydrophilic outer portion and a hydrophobic cavity are generally used for their ability to encapsulate the lipophilic compounds or groups, and therefore, for their role as protector and solubilizer of these lipophilic or lipophilic group-bearing compounds. They are thus classically found in the fields of agri-food, but also in galenic form, where they are used as excipients in pharmaceutical formulations.
    The glucopyranose units of the cyclodextrins each comprise 3 reactive hydroxyl groups, which are borne by the carbons C2, C3 and C6. Numerous derivatives have thus already been synthesized by grafting of different groups on these hydroxyl functions, among which mention may be made of hydroxypropyl-cyclodextrins, methyl-cyclodextrins, and sulphated derivatives.
    Very recently, in its patent application WO 2015/087016 A1, the Applicant has demonstrated in an original way that certain methyl-cyclodextrins, characterized by a low degree of molar substitution (MS), of between 0.05 and 1.50, could be used not as an excipient, but as a pharmaceutical active ingredient.
    The Applicant has shown in particular that these methyl-cyclodextrins of low MS were able to act effectively and specifically on lipid metabolism, by increasing the level of plasma HDL cholesterol ("good cholesterol"), and by decreasing triglyceride levels.
    In this patent application, the Applicant envisioned the possibility of a dosage form that makes it possible to take advantage both of the pharmacological properties of these methyl-cyclodextrins, but also of their encapsulation properties. In particular, it was intended to envisage a complex in which this methyl-cyclodextrin would have encapsulated a hydrophobic active ingredient having a complementary pharmacological activity.
    Unfortunately, the product used in this patent application has a relatively limited ability to solubilize lipophilic compounds.
    The main objective of the present invention was therefore to improve this solubilization capacity of methyl-cyclodextrin, in order to obtain an active / excipient of greater efficiency.
    The major constraint which the Applicant had to face is that, in accordance with what was taught in the aforementioned patent application WO 2015/087016 A1, these methyl-cyclodextrins necessarily had to have a low MS in order to be able to act effectively on the lipid metabolism. . However, it is known that the low-methylated cyclodextrins have a lower capacity to solubilize lipophilic compounds, compared to highly methylated cyclodextrins (on this subject for example: Kiss, T., Fenyvesi, F. and al .: Eur J. Pharm Sci 40 (2010) 376-380).
    Also in order to obtain a methyl-cyclodextrin which is both pharmacologically active, and both capable of more effectively encapsulating lipophilic compounds, it was necessary to reconcile properties a priori contradictory.
    Presentation of the invention
    The Applicant has succeeded after numerous studies which have resulted in the development of a methylated cyclodextrin of low MS, between 0.05 and 1.50, which, unlike the product used in this previous application for patent, has a low conductivity when in the form of an aqueous solution, less than or equal to 50 pS / cm.
    The methyl-cyclodextrin of the invention has been obtained according to a new process, involving a step of reducing the ionic species so that the conductivity of the methyl-cyclodextrin is greatly reduced. The use of methyl-cyclodextrins as solubilizer of lipophilic active principles had of course already been envisaged in the prior art. However, these methyl-cyclodextrins did not exhibit the characteristics and therefore the effectiveness of those of the invention.
    US Pat. No. 7,259,153 B2, for example, describes the solubilization of lipophilic active principles using methyl-cyclodextrins, in particular methyl-cyclodextrins (ΜβΟϋ). However these ΜβΟϋ did not have the combination of characteristics of the methyl-cyclodextrins of the invention and are much less effective for the solubilization of lipophilic compounds (see in particular the results obtained with the comparative methyl-cyclodextrin "MβCD-CP1" in the Example below).
    Note that in this patent, the solubilization problem was in principle solved by means of the use of crystallized ΜβΟϋ. The fact that these cyclodextrins require to be in crystalline form considerably limits the freedom of texturing of the product. Other documents describe more generally methods for preparing methylated cyclodextrins. Among the few documents actually describing the preparation of methyl-cyclodextrins of low MS, the Applicant has further found that the methods employed do not allow to effectively separate the ionic species and thus to obtain a product of low conductivity according to the invention.
    No. 6,602,860 B1, for example, owned by the Applicant, describes compositions comprising methyl-cyclodextrins having an MS less than 2. However, the method employed did not allow the preparation of a product of low conductivity according to the invention. . These Μβΰϋ are much less effective than the methyl-cyclodextrins of the invention for the solubilization of lipophilic compounds. (see in particular the results obtained with the comparative methyl-cyclodextrin "ΜβΟϋ ^ Ρ2" in the example below).
    In addition, these methyl-cyclodextrins, were characterized in that they were both in crystalline form and in amorphous form, or it is difficult industrially to provide a product that always has the same crystalline / amorphous ratio. In addition, the crystalline portion leads, in the presence of low levels of moisture, to the crystallization of the initially amorphous portion. This crystallization leads to a powder which has caking problems. In addition to the problem of reproducibility of the process, a relatively unstable product is thus obtained.
    Thus, the object of the present invention is to provide a methylated cyclodextrin of low MS, which is more effective than the methylated cyclodextrins of low MS of the prior art, for the solubilization of lipophilic compounds or carriers of at least one lipophilic group.
    More generally, the present invention aims to provide a means for solubilization in aqueous medium of lipophilic compounds, or carriers of at least one lipophilic group.
    The object of the present invention is in particular to provide a means for solubilization in an aqueous medium of lipophilic compounds, or carriers of at least one lipophilic group, which also makes it possible to act positively on lipid metabolism, in particular by increasing the serum level. HDL cholesterol and / or lowering triglyceride levels.
    It is another object of the present invention to provide a cyclodextrin useful for improving the chemical stability of lipophilic or lipophilic moieties, and / or for improving their delivery at and across biological membranes, and / or to increase their physical stability, and / or to convert them from a liquid form to a powder form, and / or to prevent interactions with other compounds, and / or to reduce local irritation after topical or oral administration of these lipophilic compounds or carriers of lipophilic groups, and / or to prevent their absorption in certain tissues such as the skin, and / or to obtain a prolonged release of these compounds, and / or to mask their taste, in particular their bitterness , and / or to modify their bioavailability. Summary of the invention
    The first subject of the present invention is thus a methyl-cyclodextrin having a degree of molar substitution (MS) of between 0.05 and 1.50, characterized in that it has a conductivity less than or equal to 50 μS / cm when it is in the form of a solution of distilled water at a concentration of 10%.
    Preferably, at least 50% of the methyl groups of said methyl-cyclodextrin are located at the hydroxyl borne by the C2 carbon of the glucopyranose unit.
    Preferably, the methyl-cyclodextrin is a methyl-cyclodextrin.
    Preferably, the methyl cyclodextrin is in powder form.
    Optionally, it is in amorphous form.
    In a preferred embodiment, it is in the form of an atomized product.
    The present invention also relates to a process for preparing a methyl-cyclodextrin having an MS of between 0.05 and 1.50, particularly useful for the preparation of methyl-cyclodextrins according to the invention, comprising the step of reducing the species ionic methyl-cyclodextrin, so that the conductivity of said methyl-cyclodextrin, when in the form of a solution of distilled water at a concentration of 10%, is reduced to a value less than or equal to at 50 μS / cm.
    Preferably, this process comprises the steps of: (a) etherifying a cyclodextrin with a methylating reagent, said etherification being carried out in basic medium, preferably aqueous, at a temperature of between 100 and 200 ° C., and at a temperature of passion between 1 and 10 bars; (b) reducing the ionic species of methyl-cyclodextrin obtained in step (a), so that the conductivity of said methyl-cyclodextrin, when in the form of a solution of distilled water at a concentration of 10%, reduced to less than or equal to 50 pS / cm; (c) drying the methyl-cyclodextrin obtained in step (b); (d) recovering the methyl-cyclodextrin obtained in step (c).
    Preferably, the step of reducing the ionic species is carried out by subjecting the methyl-cyclodextrin in solution, in particular in aqueous solution, to: an operation (b.1) of nano-filtration of the methyl-cyclodextrin solution, said solution having a solids content by weight of less than or equal to 20%; a demineralization operation (b.2) on an ion exchange column; - Operation (b.3) of activated carbon bleaching.
    The present invention also relates to a composition comprising a methyl-cyclodextrin according to the invention, or comprising a methyl-cyclodextrin obtained according to the method for preparing a methyl-cyclodextrin of the invention. Preferably, the composition further comprises a lipophilic compound or carrier of at least one lipophilic group.
    The present invention also relates to the use of a methyl-cyclodextrin according to the invention, or of a methyl-cyclodextrin obtained according to the process for the preparation of a methyl-cyclodextrin of the invention, for the solubilization of lipophilic compounds, or carriers of at least one lipophilic group, and / or to improve their chemical stability, and / or to improve their delivery at and across biological membranes, and / or to increase their physical stability, and / or to convert them from a liquid form to a powder form, and / or to prevent interactions with other compounds, and / or to reduce local irritation after topical or oral administration of these lipophilic or lipophilic group-bearing compounds, and / or to prevent their absorption in certain tissues such as the skin, and / or to obtain a prolonged release of these compounds, and / or to mask their taste, in particular the bitter, and / or to modify their bioavailability.
    Detailed description of the invention
    The methyl-cyclodextrins of the invention have a good ability to solubilize lipophilic agents, or carriers of lipophilic groups, while maintaining a low MS, which guarantees its pharmacological activity on lipid metabolism.
    This solubilization power is greater than that of the ΜβΟϋ used in the patent application WO 2015/087016 A1. It is also greater than that of the ΜβΟϋ objects of US Patents 7,259,153 B2, US 6,602,860 B1 and US 5,935,941 A (see the Example below).
    The methyl-cyclodextrins of the invention can thus be advantageously used for the solubilization of lipophilic active ingredients or lipophilic group carriers, in pharmaceutical compositions. In these compositions, the methyl-cyclodextrin of the invention may advantageously fulfill the function of encapsulating agent vis-a-vis this other compound, and further, the function of active principle.
    Thus, the present invention relates to a pharmaceutical composition comprising a methyl-cyclodextrin according to the present invention as active ingredient and / or as an excipient. This pharmaceutical composition may further comprise another active ingredient, preferably lipophilic or bearing lipophilic groups, especially hypoglycemic agents.
    Among these lipophilic active principles, mention may be made of hypoglycemic agents used in type 2 diabetes, which for the most part are very insoluble in water. The use of the pharmacological properties of methyl-cyclodextrin would also be very advantageous in the treatment of this pathology since the majority of patients with type 2 diabetes have, in addition to a characteristic hyperglycemia, mixed dyslipidemia. These mixed dyslipidemias are characterized by a decrease in HDL-cholesterol, and an increase in triglyceride levels, which are precisely regulated by methyl-cyclodextrins of low MS.
    Another advantage of the methyl-cyclodextrin of the invention is that the amorphous or crystalline form of the methyl-cyclodextrin of the invention has no effect on its effectiveness, which leaves a great freedom in the texturing of the product and expands the field of possible galenic forms. It may for example be entirely in amorphous form, for example in the form of an atomized product.
    The methyl-cyclodextrin of the invention is firstly characterized by its molar degree of substitution (MS), which is between 0.05 and 1.50.
    It is recalled here that the "degree of molar substitution (MS)" corresponds to the number of hydroxyl groups substituted by a methyl group, per glucopyranose unit. Note that the degree of molar substitution (MS) is different from the degree of molecular substitution (DS) which corresponds to the number of hydroxyl groups substituted by a methyl group, per molecule of cyclodextrin and which therefore takes into account the number of glucopyranose units constituting methyl-cyclodextrin.
    The MS may be conventionally determined by those skilled in the art by Proton Nuclear Magnetic Resonance (NMR), or by mass spectrometry (electrospray ionization mass spectrometry (ESI-MS) or laser desorption / ionization mass spectrometry). assisted by matrix (MALDI-MS)). Although these techniques are well known to those skilled in the art, the latter may for example refer to the methods described in the reference thesis of JACQUET Romain. "Hydrophilic cyclodextrins: characterization and study of their enantioselective and complexing properties. Use of liquid chromatography and mass spectrometry ". Thesis of chemistry and physicochemistry of compounds of biological interest. Université d'Orléans, 2006. available on http://tel.archives-ouvert.fr/docs/00/18/55/42/PDF/jacquet.pdf (accessed 27.11.2013). In particular Chapter 2, Part B (pages 59 to 83).
    Preferably, the MS is determined by NMR. In particular, it is possible to proceed according to the method described hereinafter in the example, in point B. 1.
    Preferably, the MS of the methyl-cyclodextrin according to the invention is between 0.10 and 1.40, preferably between 0.10 and 1.30, preferentially between 0.20 and 1.20, preferentially between 0.30 and 1.30 and 1.10, preferentially between 0.30 and 1.00, preferably between 0.50 and 0.90, preferably between 0.60 and 0.80, for example between 0.60 and 0.70.
    It should be noted that the methyl-cyclodextrin of the invention, although it may correspond to a pure product, generally corresponds to a mixture of methyl-cyclodextrin molecules of different structures. As a result, the MS measured is in this case an average of the substitutions that occur on all the glucopyranose units of the entire mixture of methyl-cyclodextrin molecules.
    This mixture may in particular contain residual native cyclodextrin molecules, that is to say unmethylated, but which are generally and advantageously in negligible amounts within the methyl-cyclodextrin of the invention. Preferentially, the native cyclodextrins represent less than 1.0% of the methyl-cyclodextrin, preferably less than 0.5%, more preferably still less than 0.1%; these percentages being expressed in dry weight.
    The methyl-cyclodextrin according to the invention is also characterized by its conductivity, which is less than or equal to 50 μS / cm.
    This conductivity is in particular measured on the basis of a solution of distilled water in which the methyl-cyclodextrin is at a concentration of 10%. It is in particular measured at a temperature of 25 ° C. It can easily be determined by those skilled in the art, for example according to the method recommended by the European Pharmacopoeia Reference "2.2.38. Conductivity, 01/2008: 20238 ", used in the Examples below.
    Preferably, the conductivity of the methyl-cyclodextrin according to the invention is between 0 and 45 μS / cm, preferably between 0 and 40 μS / cm, preferably between 0 and 35 μS / cm, preferably between 0 and 30 μS / cm, preferably between 0 and 25 μS / cm, preferably between 0 and 20 μS / cm. This conductivity is generally at least 1 μS / cm. It is for example chosen in the range from 1 to 15 μS / cm, or even from 1 to 10 μS / cm, or even from 5 to 10 μS / cm, or even from 6 to 10 μS / cm, or even from 7 to 10 μS. / cm, or even 8 to 10 pS / cm.
    The methyl-cyclodextrin according to the invention may be substituted on the hydroxyl borne by the C2 carbon of the glucopyranose units, or by the C3 and / or C6 carbons of the glucopyranose units, or by a combination of the C2, C3 and / or C6 carbons. preferably C2 and C6 glucopyranose units.
    This distribution of the methyl groups on the hydroxyls of the glucopyranose unit of the methyl-cyclodextrin can be classically determined by those skilled in the art by NMR.
    Preferably, at least 50% of the methyl groups of the methyl-cyclodextrin of the invention are located at the hydroxyl borne by the carbon C2 of the glucopyranose unit, for example 50 to 80%, preferably 60 to 80%, preferably 65 to 80%, preferably 70 to 80%, for example 75%.
    At the same time, the other methyl groups are generally located mainly at the level of the hydroxyl borne by the C3 and / or C6 carbon of the glucopyranose unit.
    Advantageously, the methyl-cyclodextrin of the invention comprises 7 α-D-glucopyranose units. It is therefore a methyl-cyclodextrin.
    In this case, the methyl-cyclodextrin preferably has the following substitution profile: o 0 to 5% of methyl-cyclodextrins comprise 2 methyl groups (DS of 2); 5 to 15% of methyl-cyclodextrins comprise 3 methyl groups (DS of 3); 20 to 25% of methyl-cyclodextrins comprise 4 methyl groups (DS of 4); 25 to 40% of methyl-cyclodextrins comprise 5 methyl groups (DS of 5); 15 to 25% of methyl-cyclodextrins comprise 6 methyl groups (DS of 6); 5 to 15% of methyl-cyclodextrins comprise 7 methyl groups (DS of 7); 0 to 5% of methyl-cyclodextrins comprise 8 methyl groups (DS of 8); these percentages being molar percentages, and their total sum generally being of the order of 100%, although the composition may optionally contain traces of methyl-cyclodextrins of different DS, as well as traces of native cyclodextrin, that is, ie unmethylated.
    The substitution profile may be conventionally determined by those skilled in the art, for example by ESI-MS or MALDI-TOF-MS. Although these techniques are well known to those skilled in the art, the latter may for example refer to the methods described in Romain JACQUET's thesis cited above, in Chapter 2, Part B, points 11.3 and 11.2 (pages 67 to 82) and in Appendix II. Generally and advantageously, the methyl-cyclodextrin according to the invention has a reducing sugar content of less than 1.0% by dry weight, preferably less than 0.5%. Generally and advantageously, the methyl-cyclodextrin of the invention comprises less than 100 ppm by dry weight of phosphates, preferably less than 50 ppm, preferentially less than 10 ppm, and preferably even less than 5 ppm. Generally and advantageously, the methyl-cyclodextrin of the invention comprises less than 20 ppm by dry weight of methylating agent, in particular dimethyl sulphate, preferably less than 10 ppm, preferably less than 5 ppm, and preferably even less than 2 ppm. Generally and advantageously, the methyl-cyclodextrin of the invention comprises less than 1.0% of alkali metal halide salts, preferably less than 0.5%, preferentially less than 0.2%, and even more preferably less than 0%. 1%; this percentage being expressed as dry weight of alkali metal halide salts relative to the total dry weight of said methyl-cyclodextrin.
    Preferably, the methyl-cyclodextrin of the invention comprises: less than 100 ppm by dry weight of phosphates, preferably less than 50 ppm, preferentially less than 10 ppm, and preferably even less than 5 ppm; less than 20 ppm by dry weight of methylating agent, in particular of dimethylsulphate, preferably less than 10 ppm, preferably less than 5 ppm, preferentially still less than 2 ppm; and less than 1.0% of alkali metal halide salts, preferably less than 0.5%, preferentially less than 0.2%, and still preferably less than 0.1%; this percentage being expressed as dry weight of alkali metal halide salts relative to the total dry weight of said methyl-cyclodextrin. Generally and advantageously, the methyl-cyclodextrin of the invention has an absorbance at a wavelength of 245 nm to 270 nm, less than 0.5 AU, preferentially less than 0.3A.U, more preferably less than 0, 2A.U; said absorbance being determined by UV / vis spectrophotometry, for an aqueous solution comprising 100 mg of said methyl-cyclodextrin per ml of solution, in a cell having a path length of 1 cm.
    This low absorbance advantageously represents a minimal reactivity of the methyl-cyclodextrin vis-à-vis other compounds.
    Indeed, the degradation agents of the pharmaceutical active principles have the particularity of having an absorption maximum at a wavelength of 245 nm to 270 nm. It is therefore these degradation agents that are measured spectrophotometrically at these wavelengths. By "degradation agent of pharmaceutical active ingredients" is meant in particular compounds, fragments, or related that degrade a pharmaceutical active ingredient in an aqueous solution. These degradation agents typically comprise compounds with a molecular weight of less than 1000 Da, such as those generated by the preparation of methyl-cyclodextrins, for example glycoside moieties, ring-opened cyclodextrin molecules, reducing sugars, glucose degradation products such as 3,4-dideoxyglucosone-3-ene, carbonyl-bearing compounds such as 2-furaldehyde, or 5-hydroxymethyl-2-furaldehyde. Generally and advantageously, the methyl-cyclodextrin of the invention has an absorbance at a wavelength of 320 nm to 350 nm, less than 0.5 AU, preferentially less than 0.2 AU, preferentially still less than 0.1. AT ; said absorbance being determined by UV / vis spectrophotometry, for an aqueous solution comprising 100 mg of said methyl-cyclodextrin per ml of solution, in a cell having a path length of 1 cm.
    This absorbance, measured from 320 nm to 350 nm, makes it possible in particular to detect the coloring agents, which are capable of interacting with the active agents that may be present.
    The methyl-cyclodextrin of the invention may be further grafted with other chemical groups than methyl groups, in a small proportion, and as long as this does not contravene the properties sought in the present invention.
    Preferably, the methyl-cyclodextrin of the invention does not comprise other groups than methyl groups. In particular, it is preferably free of hydroxyalkyl groups, in particular hydroxyethyl groups.
    In a particular and advantageous embodiment, the methyl-cyclodextrin of the invention is in pulverulent form. It can in this case be in amorphous form, in crystalline form, or in the form of a mixture of these two forms. It is preferably either in amorphous form or in crystalline form, that is to say that, preferably, it is not in the form of a mixture of these two forms. Most preferably, the methyl-cyclodextrin of the invention is in amorphous form.
    Advantageously, the methyl-cyclodextrin of the invention is in the form of an atomized product, that is to say in the form of a powder obtained by spray-drying a solution of this methyl-cyclodextrin, for example realized in a single-effect atomization tower.
    Advantageously, the pulverulent methyl-cyclodextrin of the invention has a moisture content of less than 10%, for example less than 5%, for example between 1 and 5%; this percentage corresponding to the weight of water relative to the total weight of said powdery methyl-cyclodextrin. The invention relates to a process for the preparation of a methyl-cyclodextrin having an MS of between 0.05 and 1.50, particularly useful for the preparation of methyl-cyclodextrins according to the invention, comprising the step of reducing the ionic species methyl-cyclodextrin, so that the conductivity of said methyl-cyclodextrin, when in the form of a solution of distilled water at a concentration of 10%, is reduced to a value less than or equal to 50 μS / cm.
    More particularly, the invention also relates to a process for the preparation of a methyl-cyclodextrin having an MS of between 0.05 and 1.50, particularly useful for the preparation of methyl-cyclodextrins according to the invention, comprising the steps: a) etherifying a cyclodextrin with a methylating reagent, said etherification being carried out in basic medium, preferably aqueous, at a temperature between 100 and 200 ° C, and a passion of between 1 and 10 bar; (b) reducing the ionic species of methyl-cyclodextrin obtained in step (a), so that the conductivity of said methyl-cyclodextrin, when in the form of a solution of distilled water at a concentration of 10%, reduced to less than or equal to 50 pS / cm; (c) drying the methyl-cyclodextrin obtained in step (b); (d) recovering the methyl-cyclodextrin obtained in step (c).
    Preferably, the methylation reagent to which step (a) refers is dimethylsulfate.
    Preferably, the etherification step (a) is carried out at a temperature of between 90 and 190 ° C., preferably between 100 and 180 ° C., preferably between 110 and 170 ° C., preferentially between 120 and 160 ° C., preferably between 130 and 160 ° C. 150 ° C, for example equal to 140 ° C.
    Preferably, the etherification step (a) is carried out at a pressure of between 2 and 9 bar, preferably between 2 and 8 bar, preferably between 2 and 7 bar, preferably between 2 and 6 bar, preferably between 3 and 5 bar. for example equal to 4 bars.
    The reaction medium of step (a) can advantageously be made basic by the addition of calcium hydroxide. The reaction may then be, for example, neutralized with sulfuric acid. Step (b) may in particular be carried out by subjecting the methyl-cyclodextrin in solution, in particular in aqueous solution, to: an operation (b.1) of nano-filtration of the methyl-cyclodextrin solution, said solution having a solids content by weight of not more than 20%; a demineralization operation (b.2) on an ion exchange column; - operation (b.3) of activated carbon bleaching; said steps (b.1), (b.2) and (b.3) being preferentially carried out in this order or in the following order: (b.1), (b.3) and (b.2). Step (b) may be preceded by a filtration or wiping and washing step, in particular in order to remove the calcium sulphate that may be formed (depending on the methylation reagent chosen, as well as the acid used to neutralize the reaction).
    Preferably, the drying step (c) is a spray drying step.
    This atomization can be a single-effect or multiple-effect atomization. In the case of a multiple-effect atomization, the atomizer is coupled with a fluidized bed, possibly integrated with the atomization tower, which makes it possible to agglomerate the particles formed by atomization. This latter method is particularly advantageous if it is desired to obtain powders of greater average diameter, and as a function of the desired flow for the resulting powder. The invention also relates to a composition comprising a methyl-cyclodextrin according to the invention, or comprising a methyl-cyclodextrin obtained according to the method for preparing a methyl-cyclodextrin of the invention.
    The composition according to the invention preferably further comprises at least one lipophilic compound or carrier of at least one lipophilic group.
    It may for example be hydrophobic compounds, that is to say conventionally poorly soluble compounds, very insoluble or even practically insoluble in water, at room temperature (15-25 ° C). By "poorly soluble compound in water" is conventionally meant that a volume of water of 100 to 1000 ml is necessary to dissolve 1 gram of said compound. For a "very low water-soluble compound," this volume of water is more than 1,000 mL and up to 10,000 mL. For a "practically insoluble compound in water", this volume of water is more than 10,000 mL. In this regard, see in particular the definition given in the European Pharmacopoeia Reference "1.4. Monographs, 07/2014: 10000 ".
    Preferably, the lipophilic compound or carrier of at least one lipophilic group to which the invention refers is a pharmaceutical active ingredient, preferentially chosen from hypoglycemic agents and their mixtures. Hypoglycemic agents essentially comprise metformin, sulfonylureas such as glibenclamide, gliclazide, glimepiride, glipizide, or gliquidone, glitazones, gliptins, GLP-1 (Glucagon-Like Petide-1) agonists, such as exenatide and liraglutide, acarbose, nateglinide and repaglinide. Preferentially, this hypoglycemic agent is chosen from sulphonylureas and is most preferably glipizide.
    Preferably, the compositions of the invention are pharmaceutical compositions, for example for use in the treatment and / or prevention of type 2 diabetes and / or its complications. The present invention also relates to the use of a pharmaceutical composition according to the present invention for the manufacture of a medicament, in particular for the treatment and / or prevention of type 2 diabetes and / or its complications. It also relates to a method of treating and / or preventing type 2 diabetes and / or its complications in a subject comprising administering a therapeutically effective amount of a pharmaceutical composition according to the present invention.
    The compositions of the invention may be in any galenic form which a person skilled in the art deems appropriate, depending on the intended use. They may for example be in liquid, solid or semi-solid form. It may for example be solutions, suspensions, dispersions, emulsions, pellet, granules, films, powders, gels, creams, ointments, pasta, sticks, tablets, hard capsules, soft capsules, osmotic devices, patches.
    The compositions of the invention may further comprise any other additional and customary compound, as long as this does not contravene the properties sought in the present invention. These compounds are typically selected according to the dosage form selected for the composition.
    The compositions of the invention are capable of being administered orally, parenterally, or cutaneously or mucosally. The parenteral route includes, for example, subcutaneous, intravenous, intramuscular or intraperitoneal administration, although the latter is rather reserved for the animal. The mucosal route includes, for example, administration via the nasal route, the pulmonary route, and the rectal mucosa. The dermal route comprises, for example, the dermal route, in particular via a transdermal device, typically a patch.
    Finally, the invention relates to the use of a methyl-cyclodextrin according to the invention, or of a methyl-cyclodextrin obtained according to the process for the preparation of a methyl-cyclodextrin of the invention, for the solubilization in aqueous medium of lipophilic compounds or carriers of at least one lipophilic group, said compound being preferentially as defined before. The invention also relates to the use of a methyl-cyclodextrin according to the invention, or a methyl-cyclodextrin obtained according to the method for preparing a methyl-cyclodextrin of the invention, for improving the chemical stability of compounds lipophilic or carriers of at least one lipophilic group, and / or to improve their delivery at and across biological membranes, and / or to increase their physical stability, and / or to convert them from a liquid form to a form powder, and / or to prevent interactions with other compounds, and / or to reduce local irritation after topical or oral administration of these lipophilic or lipophilic group-bearing compounds, and / or to prevent their absorption at the level of certain tissues such as the skin, and / or to obtain a prolonged release of these compounds, and / or to mask their taste, in particular their bitterness, and / or to modify their bio availability.
    Note that in the present invention, it is understood that the expression "between X and Y" covers a range of values excluding the cited terminals.
    It is furthermore understood that when referring to the percentage concentration of a substance in solution, this concentration expresses the number of grams of said substance per 100 ml of said solution. This mass in grams is indeed a dry mass, that is to say it excludes in particular the mass of water possibly present in the substance in its powder form, before solubilization. The invention will be better understood with the aid of the examples which follow, which are intended to be illustrative and not limiting.
    figure
    FIG. 1 describes the ratio of improvement of the solubility as a function of the concentration of methyl-cyclodextrin for several samples of methyl-cyclodextrin ("ΜβΟϋ-ΙΝ" "ΜβΟϋ-ΟΡ1", "ΜβΟϋ-ΟΡ2" and "ΜβΟϋ -ΟΡ3 >>).
    Example
    In the following tests, a methyl β-cyclodextrin according to the invention ("ΜβΟϋ-ΙΝ") was compared with methyl β-cyclodextrins using methods of the prior art ("ΜβΟϋ-ΟΡ1", "ΜβΟϋ- ΟΡ2 "and" ΜβΟϋ-ΟΡ3 ").
    The inventors have ensured that these ΜβΟϋ all have an MS of 0.7, so that these ΜβΟϋ can be compared effectively on the basis of the conductivity criterion. A. Methyl-B-cyclodextrins (MBCD) used 1. Preparation of an MBCD according to the invention (MBCD-IN)
    Native β-cyclodextrin was etherified with dimethylsulfate in aqueous media and in the presence of calcium hydroxide under the following conditions of temperature and pressure: 140 ° C / 4 bar. The reaction medium was then neutralized with sulfuric acid.
    The reaction product was then wrung (Dorr-Oliver wringer BW630H) and washed to remove the calcium sulphate formed during the reaction. The washing was in particular carried out by spraying nozzle with demineralised water heated to 70 ° C. 3.5 tons of reaction product at 23% solids content were thus obtained.
    The ionic species of the reaction product thus obtained were separated by the following operations: nanofiltration of the solution adjusted to 20% solids content; demineralization on an ion exchange column; - discoloration with activated charcoal. The nanofiltration step has in particular been carried out under the following conditions: use of AFC30 membranes; use of two tubes in parallel of 1.7 m2 (3.4 m2 in total); high pressure pump of 2.7 m2 / h; against regulated pressure at 20 bar input module; solutionβΟϋ solution adjusted to 20% solids content, brought to a temperature of 55 ° C and a pH of 5.5; flow rate of 70 to 85 L / h / m2; outlet pressure of 18 bar. Six filtrations were thus carried out. The demineralization step has in particular been carried out under the following conditions: treatment at a temperature below 40 ° C, 50 L / h, at 20% solids content: cationic (Amberlite 252); 25 liters; 1.8 eq / L; anionic (Amberlite IRA 910); 40 liters; 1.1 eq / L; o mixed bed; 30 liters; 2 tanks of 700 L were demineralized before regeneration. The activated carbon bleaching step (NORIT SX plus) was carried out in particular under the following conditions: solution of ΜβΟϋ at 20% dry matter content treated with 1% black; stirring 1 hour; pH 5 - 5.5; ambient temperature ; filtration on the sleeve of 11 pm, then 8 pm and finally 0.22 pm.
    The ΜβΟϋ thus obtained was then concentrated so as to have a solids content by weight of 30%, using an evaporator (NIRO), in particular under the following conditions: feed rate of 100 L / h; product temperature of 62 ° C; Pressure of 200 mbar.
    The solution thus obtained was dried by single-effect atomization (NIRO atomizer). The conditions were in particular the following: spray solution adjusted to a temperature of 70 ° C. and a pH of 6.5-7; filtraton of the solution (0.22 μm); inlet air temperature 250 ° C; air temperature cfe regulated output at 115 ° C; air flow of 120 Nm3 / h; depression adjusted to 35 mm of water; atomized product flow of 6.8 to 7 kg / h.
    The pulverulent ΜβΟϋ thus obtained (ΜβΟϋ-ΙΝ) had a moisture content of 3.5%, a reducing sugar content of 0.3% and a residual native β-cyclodextrin content of less than 0.1%. 2. MBCD comparatives (MBCD-CP1, -CP2 and -CP3)
    The comparative methyl-cyclodextrin "M8CD-CP1" corresponds to that used in US Pat. No. 7,259,153 B2 and referred to as "Cryst. Methylated β-CD "in this patent. Although no process for the preparation of this ΜβΟϋ is described in this patent, and that this product is not commercially available, the inventors assumed that it was prepared according to US Pat. No. 5,935,941 A. In fact, this patent is cited as a promising basis for the preparation of the ΜβΟϋ of US Pat. No. 7,259,153 B2. The inventors have in particular based on Example 15 of US Pat. No. 5,935,941 A, the only example illustrating the preparation of methylated cylodextrins. In particular, the reaction product was treated according to the methods described in Example 1 of this document.
    Comparative methyl-cyclodextrin "ΜβΟϋ-ΟΡ2" was prepared according to US Pat. No. 6,602,860 B1. In particular, the reaction product was treated according to the methods described in Example 1 of this document.
    Comparative methyl-cyclodextrin "ΜβΟϋ-ΟΡ3" corresponds to the product marketed under the name KLEPTOSE® Crysmeb, used in the patent application WO 2015/087016 A1. This product is in particular obtained according to US Pat. No. 9,935,941 A, except that it is spray-dried. B. Characterization
    The characteristics of the methyl-cyclodextrins ΜβΟϋ-ΙΝ, ΜβΟϋ-ΟΡ1, ΜβΟϋ-ΟΡ2 and ΜβΟϋ-ΟΡ3 were determined according to the following methods. 1. Determination of the degree of molar substitution (MS) and the substitution profile. The MS was determined by proton NMR (on a 250 MHz DPX device Advance (Bruker, Rheinstetten, Germany)). The measurements were conducted at 25 ° C. Calibration was performed with signal D20. Samples of ΜβΟϋ and native cyclodextrin, that is to say unmethylated, were prepared at a concentration of 5 mg in 0.75 ml of D20. The solutions were evaporated to dryness under a stream of nitrogen and then reconstituted in 0.75 ml of D20. This operation was repeated twice in order to ensure a total exchange of the protons of the hydroxyl functions. The MS was calculated from the difference in integration between the native cyclodextrin spectrum and that of the methyl-cyclodextrin according to the invention. The NMR spectrum also allowed the calculation of the substitution profile. 2. Determination of conductivity. The conductivity was determined at 25 ° C according to the method recommended by the European Pharmacopoeia Reference "2.2.38. Conductivity, 01/2008: 20238 ", based on a solution of 100 mL, at 10% of ΜβΟϋ. In particular, 10 dry grams of ΜβΟϋ were placed in a 100 mL volumetric flask. Distilled water with a resistivity greater than 500,000 ohm.cm was added (q.s.p. 100 mL).
    The conductivity of this solution was in particular determined using an electronic conductivity meter (KNICK 703) equipped with its measuring cell and verified according to the procedure described in the instruction relating thereto.
    The results obtained are shown in Table 1.
    Table 1
    ND: not determined C. Solution for solubilization of qlipizide
    The methyl-cyclodextrin ΜβΟϋ-ΙΝ according to the invention and the comparative methyl-cyclodextrins ΜβΟϋ-ΟΡ1, ΜβΟϋ-ΟΡ2 and ΜβΟϋ-ΟΡ3 were evaluated for their capacity to solubilize glipizide in distilled water, according to the following method: 6 solutions at 0, 1,2, 10 and 15% of ΜβΟϋ were prepared, for each ΜβΟϋ. Distilled water was used as a control solution. These solutions were stirred at room temperature. Glipizide was added milligram per milligram until it no longer solubilized. The limiting amount of glipizide solubilizing was noted for each solution, which made it possible to calculate the number of mg of solubilized glipizide per mL of solution.
    The solubility improvement ratio gives the factor by which the solubility is increased in the presence of a defined methyl-cyclodextrin concentration. It is calculated as follows:
    with: "Smcd" expressed as mg of solubilized glipizide per mL of methyl-cyclodextrin solution; "Sh2o" expressed mg of solubilized glipizide per mL of water.
    The results are shown in Figure 1.
    It is found that the solubility improvement ratio is much higher for the methyl-cyclodextrin ΜβΟϋ-ΙΝ according to the invention, compared to the methyl-cyclodextrins ΜβΟϋ-ΟΡ1, ΜβΟϋ-ΟΡ2 and ΜβΟϋ-3, which do not comply with to the invention.
    It can be deduced that at low MS, a methyl-cyclodextrin having a conductivity less than or equal to 50 μS / cm, such as the methyl-cyclodextrin ΜβΟϋ-ΙΝ according to the invention, is a much better solubilizer for lipophilic compounds or compounds bearing lipophilic groups.
    权利要求:
    Claims (12)
    [1" id="c-fr-0001]
    claims
    Methyl cyclodextrin having a degree of molar substitution (MS) of between 0.05 and 1.50, characterized in that it has a conductivity of less than or equal to 50 μS / cm when it is in the form of a solution of distilled water at a concentration of 10%.
    [2" id="c-fr-0002]
    2. Methyl-cyclodextrin according to claim 1, characterized in that at least 50% of the methyl groups of said methyl-cyclodextrin are located at the hydroxyl borne by the carbon C2 of the glucopyranose unit.
    [3" id="c-fr-0003]
    3. A methyl cyclodextrin as claimed in claim 1 or 2, characterized in that it is a methyl-β-cyclodextrin.
    [4" id="c-fr-0004]
    4. Methyl-cyclodextrin according to any one of claims 1 to 3, characterized in that it is in powder form.
    [5" id="c-fr-0005]
    5. Powdered methyl-cyclodextrin according to claim 4, characterized in that it is in amorphous form.
    [6" id="c-fr-0006]
    6. Methyl cyclodextrin according to any one of claims 1 to 5, characterized in that it is in the form of an atomized product.
    [7" id="c-fr-0007]
    7. A process for preparing a methyl-cyclodextrin having an MS of between 0.05 and 1.50, comprising the step of reducing the ionic species of the methyl-cyclodextrin, so that the conductivity of said methyl-cyclodextrin cyclodextrin, when in the form of a solution of distilled water at a concentration of 10%, is reduced to a value less than or equal to 50 μS / cm.
    [8" id="c-fr-0008]
    A process for preparing a methyl-cyclodextrin having a molar degree of substitution (MS) of from 0.05 to 1.50, comprising the steps of: (a) etherifying a cyclodextrin with a methylating reagent, said etherification being carried out in a basic medium, preferably aqueous, at a temperature of between 100 and 200 ° C., and at a pressure of between 1 and 10 bar; (b) reducing the ionic species of methyl-cyclodextrin obtained in step (a), so that the conductivity of said methyl-cyclodextrin, when in the form of a solution of distilled water at a concentration of 10%, reduced to less than or equal to 50 pS / cm; (c) drying the methyl-cyclodextrin obtained in step (b); (d) recovering the methyl-cyclodextrin obtained in step (c).
    [9" id="c-fr-0009]
    9. Process for the preparation of a methyl-cyclodextrin according to either of Claims 7 and 8, characterized in that the step of reducing the ionic species is carried out by subjecting the methyl-cyclodextrin in solution, in particular in aqueous solution, in: - a nano-filtration operation (b.1) of the methyl-cyclodextrin solution, said solution having a solids content by weight of less than or equal to 20%; a demineralization operation (b.2) on an ion exchange column; - Operation (b.3) of activated carbon bleaching.
    [10" id="c-fr-0010]
    10. A composition comprising a methyl-cyclodextrin as defined in any one of claims 1 to 6, or comprising a methyl-cyclodextrin obtained by the process as defined in any one of claims 7 to 9.
    [11" id="c-fr-0011]
    11. The composition of claim 10 further comprising a lipophilic compound or bearing at least one lipophilic group.
    [12" id="c-fr-0012]
    12. Use of a methyl-cyclodextrin as defined in any one of claims 1 to 6, or a methyl-cyclodextrin obtained according to the process as defined in any one of claims 7 to 9, for the solubilizing lipophilic compounds, or carriers of at least one lipophilic group, and / or to improve their chemical stability, and / or to improve their delivery at and across biological membranes, and / or to increase their physical stability, and / or to convert them from a liquid form to a powder form, and / or to prevent interactions with other compounds, and / or to reduce local irritation after topical or oral administration of these lipophilic or lipophilic groups, and / or to prevent their absorption in certain tissues such as the skin, and / or to obtain a prolonged release of these compounds, and / or to mask their taste, in part icular their bitterness, and / or to modify their bioavailability.
    类似技术:
    公开号 | 公开日 | 专利标题
    Al-Marzouqi et al.2006|Phase solubility and inclusion complex of itraconazole with β-cyclodextrin using supercritical carbon dioxide
    US7202233B2|2007-04-10|Alprazolam inclusion complexes and pharmaceutical compositions thereof
    EP0714386B1|1999-03-10|Water-soluble nimesulide salt, and uses thereof for the treatment of inflammations
    EP3362487A1|2018-08-22|Novel methylated cyclodextrins and methods for the production thereof
    CA2723119C|2013-08-06|Pharmaceutical compound comprising a strontium salt, vitamin d and a cyclodextrin
    EP1675876A2|2006-07-05|Cyclodextrin amphiphilic derivatives, method for preparing same and uses thereof
    EP0736044B1|1998-05-06|Cyclodextrin derivatives for solubilising hydrophobic chemical compounds such as drugs, and methods for preparing same
    CZ20031878A3|2004-10-13|Mixtures of modafinil compound and cyclodextrin
    EP1974751A1|2008-10-01|Formulations for non-steroidal anti-inflammatory drugs
    Darekar et al.2016|Characterization and in vivo evaluation of lacidipine inclusion complexes with β-cyclodextrin and its derivatives
    EP1434567B1|2007-12-19|Method for preparing a compound for interaction of active substances with a porous support using supercritical fluid
    WO2003063805A2|2003-08-07|Cosmetic or dermatological use of vitamin a or the esters thereof in combination with a partly methylated beta-cyclodextrin
    EP2529742B1|2013-11-20|Pharmaceutical composition comprising dapagliflozin and cyclodextrin
    KR101131296B1|2012-03-30|An inclusion complex composed of disulfiram and a cyclodextrin, useful for the treatment of alcohol and cocaine dependences
    CA3104568A1|2020-01-02|Novel hydroxypropyl-b-cyclodextrin and process for the production thereof
    WO2006042858A2|2006-04-27|Complex comprising an antibiotic, a cyclodextrin and an interaction agent
    FR3083234A1|2020-01-03|NOVEL HYDROXYPROPYL-BETA-CYCLODEXTRINS AND PROCESSES FOR THEIR PREPARATION
    EP2416769B1|2018-09-26|Method for preparing molecular complexes between adapalene and cyclodextrins
    US6864246B2|2005-03-08|Anilide and cyclodextrin complexes, their preparation and their use as medicine in particular for treating dyslipidemiae
    FR2693728A1|1994-01-21|Process for producing partially methylated cyclodextrins and compounds obtained
    Al-Derbali2016|Formulation and evaluation of zidovudine cyclodextrin inclusion complex to enhance acid lability and palatability
    EP2008665A1|2008-12-31|Injectable formulation for photodynamic therapy
    WO1999061483A1|1999-12-02|Region-selective method for preparing cyclodextrin c-6 monosulphonyl derivatives
    HU0900229A2|2010-12-28|Process for preparing of sulphobutylated cyclodextrins of pharmaceutical additive quality
    同族专利:
    公开号 | 公开日
    EP3362487A1|2018-08-22|
    CN108137714A|2018-06-08|
    US11098135B2|2021-08-24|
    US20180319903A1|2018-11-08|
    CN108137714B|2021-04-09|
    FR3042501B1|2017-11-03|
    WO2017064436A1|2017-04-20|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    EP0193850A2|1985-02-28|1986-09-10|Sanraku Incorporated|Partially methylated cyclodextrins and process for producing the same|
    JPS62220501A|1986-03-20|1987-09-28|Kao Corp|Methylated beta-cyclodextrin|
    WO1994002516A1|1992-07-17|1994-02-03|Orsan|Method of producing partially methylated cyclodextrines and compounds obtained|
    US5710268A|1993-10-01|1998-01-20|Consortium Fur Elektrochemische Industrie Gmbh|Process for the preparation of methylated cyclodextrin derivatives, and their use as solubilizers|
    CN1709918A|2005-05-17|2005-12-21|浙江大学|Process for synthesizing random methylated beta-cyclodextrin|
    BE1006873A6|1993-03-26|1995-01-10|Merkus Franciscus W H M|Administration for drafting nasal insulin delivery.|
    US5712117A|1995-02-08|1998-01-27|Zymogenetics, Inc.|Cytoplasmic antiproteinase-2 and coding sequences|
    US5935941A|1997-10-24|1999-08-10|Pitha; Josef|Alkylations of cyclodextrins leading to derivatives which have a ridgidly extended cavity|
    AU3643301A|1999-11-12|2001-05-30|Pitha & Pitha Llc|Crystalline mixtures of partial methyl ethers of beta-cyclodextrin and related compounds|
    US7259153B2|2003-02-03|2007-08-21|Supernus Pharmaceuticals|Drug formulation and delivery using crystalline methylated cyclodextrins|
    JP2015508846A|2012-02-28|2015-03-23|サイデックス・ファーマシューティカルズ・インコーポレイテッド|Alkylated cyclodextrin compositions and methods for their preparation and use|
    FR3014694B1|2013-12-13|2016-11-11|Roquette Freres|METHYL-CYCLODEXTRIN-BASED COMPOSITIONS FOR THE TREATMENT AND / OR PREVENTION OF DISEASES BY INCREASING THE CHOLESTEROL-HDL RATE|EP3622959A1|2018-09-17|2020-03-18|Roquette America, Inc.|Cyclodextrin for protecting cells upon cryopreservation|
    CN111111446A|2019-12-23|2020-05-08|天津膜天膜科技股份有限公司|Membrane method for separating and purifying cyclodextrin and derivatives thereof|
    CN112062877B|2020-06-09|2021-05-25|北京博诺安科科技有限公司|Methylated-beta-cyclodextrin, and preparation method, characterization method and application thereof|
    法律状态:
    2016-10-28| PLFP| Fee payment|Year of fee payment: 2 |
    2017-04-21| PLSC| Publication of the preliminary search report|Effective date: 20170421 |
    2017-10-31| PLFP| Fee payment|Year of fee payment: 3 |
    2018-10-30| PLFP| Fee payment|Year of fee payment: 4 |
    2019-10-31| PLFP| Fee payment|Year of fee payment: 5 |
    2020-10-30| PLFP| Fee payment|Year of fee payment: 6 |
    2021-10-29| PLFP| Fee payment|Year of fee payment: 7 |
    优先权:
    申请号 | 申请日 | 专利标题
    FR1559832A|FR3042501B1|2015-10-16|2015-10-16|NOVEL METHYLATED CYCLODEXTRINS AND PROCESSES FOR THEIR PREPARATION|FR1559832A| FR3042501B1|2015-10-16|2015-10-16|NOVEL METHYLATED CYCLODEXTRINS AND PROCESSES FOR THEIR PREPARATION|
    US15/767,958| US11098135B2|2015-10-16|2016-10-14|Methylated cyclodextrins and methods for the production thereof|
    PCT/FR2016/052658| WO2017064436A1|2015-10-16|2016-10-14|Novel methylated cyclodextrins and methods for the production thereof|
    CN201680058923.XA| CN108137714B|2015-10-16|2016-10-14|Methylated cyclodextrins and process for their production|
    EP16794381.0A| EP3362487A1|2015-10-16|2016-10-14|Novel methylated cyclodextrins and methods for the production thereof|
    [返回顶部]